Cellular Dynamics International, Inc. (CDI), the world’s largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell™ Services. These services include novel iPS cell line reprogramming, genetic engineering and differentiation of iPS cells into commercially available iCell® terminal tissue cells (for example, heart or nerve cells).
“CDI’s mission is to be the top developer and manufacturer of standardized human cells in high quantity, quality and purity and to make these cells widely available to the research community. Our MyCell Services provide researchers with unprecedented access to the full diversity
International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.
Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.
The very first human trials of a treatment using induced pluripotent stem cells (iPS cells) in Japan will begin as early as next year, the government-backed Riken research institute announced on June 12.
Speaking at a meeting of the Japanese Society for Regenerative Medicine in Yokohama, research team leader Masayo Takahashi of the Riken Center for Developmental Biology detailed plans to begin using iPS treatments on patients with a degenerative eye condition. Transplanted iPS cells have not developed into cancer in animal testing, and the clinical trial will go ahead now that it’s confirmed that similar procedures do not pose
Researchers in Japan said on Wednesday they have succeeded in growing human kidney tissue from stem cells for the first time in a potential breakthrough for millions with damaged organs who are dependent on dialysis.
Kidneys have a complex structure that is not easily repaired once damaged, but the latest findings put scientists on the road to helping a diseased or distressed organ fix itself.
Kenji Osafune of Kyoto University said his team had managed to take stem cells — the “blank slates” capable of being programmed to become any kind of cell in the body — and nudge them specifically
All over the world there are desperate patients looking for institutions that promise to heal them with stem cells. But the treatments that are promised must be controlled and regulated, said two scholars in Science magazine. Today, recognized treatments with stem cells involve blood diseases or immune system defects, wrote the Thai researcher Sorapop Kiatpongsan and his Japanese colleague Douglas Sipp. In reality, many other treatments have been offered without proof of their effectiveness.
For example, treatments are being offered to cure heart disease, autism, Down’s syndrome, and epilepsy. These treatments are ineffective and are mainly